Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + gamma-aminobutyric acid + codeine phosphate is an oral combination product marketed as **Theracodeine-300**, a convenience kit that combines acetaminophen and codeine phosphate tablets with the medical food Theramine, which contains gamma-aminobutyric acid as part of a proprietary amino acid blend. The analgesic effect is driven primarily by acetaminophen, a centrally acting non-opioid analgesic and antipyretic, together with codeine phosphate, an opioid analgesic whose active metabolite engages mu-opioid receptors to reduce pain perception. The gamma-aminobutyric acid component is included via the Theramine medical food for dietary management of pain and inflammatory conditions rather than as a conventional approved analgesic active pharmaceutical ingredient. The product is intended for the relief of mild to moderately severe pain and is associated with the known opioid risks of codeine, including respiratory depression, misuse, and dependence potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + gamma-aminobutyric acid + codeine phosphate.